INTRODUCTION
New therapies are needed to treat disease attributed to hematologic genetic (i.e. Fanconi anemia, hemoglobinopathies) and infectious disease (i.e. HIV/AIDS). Autologous or allogeneic hematopoietic stem cell (HSC) transplantation in which the graft has been gene-modified offers a potential cure for hematopoietic or immune system failure. However, appropriate autologous HSCs for genetic modification are often unavailable and limited availability of MHC matched donors significantly restricts allogeneic treatment options. 1 In addition, patients receiving allogeneic grafts also may experience acute and chronic life-threatening complications. 2 Induced pluripotent stem cell (iPSC) therapies are a tractable alternative to allogeneic cell transplantation, because they represent an unlimited source of autologous, patient-specific cells. [3] [4] [5] [6] [7] However, in vivo preclinical models for long-term functional and safety analysis of iPSCrelated therapeutics are limited by model organism life span and further compromised in that available infectious disease models fail to recapitulate human disease. Nonhuman primate (NHP) studies permit longitudinal evaluation of iPSC-derived hematopoietic progenitor cells (HPCs) in an autologous setting and provide assays for safety validation, therapeutic benefit, and terminal cell fate and function. Furthermore, findings in NHP models generally translate well to human applications. 8 Thus, to critically evaluate the longitudinal therapeutic benefits, risks, and fate of iPSC-derived HPCs in vivo, an appropriate NHP model is required.
Toward modeling novel therapies for blood related diseases and HIV/AIDS in the pigtail macaque, we have previously shown stable engraftment of bone marrow and peripheral blood derived autologous CD34 + cells expressing therapeutic and anti-HIV transgenes. [9] [10] [11] The CD34-enriched fraction from mobilized blood or bone marrow reconstitutes the hematopoietic system indicating that enriched CD34 high fraction contains a subset of cells that are long-term repopulating hematopoietic stem cells (LT-HSCs). We have also recently shown that transplantation with HSCs modified to express the anti-HIV protein C46 reduces viral load in SHIV-infected monkeys, and supports partial recovery of immune function (manuscript For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From submitted). As iPSCs represent an inexhaustible source for generation of virus resistant genemodified CD34
+ cells and hematopoietic progeny, the pigtail macaque allows for testing of SHIVspecific iPSC-derived hematopoietic cell therapeutics in vivo while in parallel assessing the long-term safety of iPSC hematopoietic progeny.
To address safety concerns, we previously generated and characterized several MniPSC lines 12, 13 and engineered MniPSCs to express an inducible suicide gene. 13 Scale-up and quality control of therapeutic cell production to attain an appropriate cell dose for transplantation in the monkey or a patient must meet the following criteria: 1) a relatively efficient hematopoietic induction protocol, 2) a well-established purification method to enrich for the target therapeutic population (CD34 + cells) and simultaneously deplete residual undifferentiated cells, and 3) a strategy to expand primitive CD34 + cells without loss of multipotency.
Production of sufficient iPSC-derived HPCs for engraftment will likely require ex vivo expansion. To this end, novel factors that maintain and expand primitive HSCs ex vivo have been identified, including StemRegenin1 (SR1), an aryl hydrocarbon receptor (AhR) antagonist 14 and prostaglandin-E 2 (PGE2), 15 both involved in HSC homeostasis. Several groups have shown that bone morphogenetic protein (BMP) and Wnt pathways specify hematopoietic fate, and that activation of these pathways impacts lineage development from mouse and human PSCs. [16] [17] [18] [19] Here we describe a novel, chemically-defined differentiation, expansion and purification strategy that meets scale-up and quality control criteria, relying upon sequential modulation of the BMP, Wnt and AhR pathways to generate HSC-like cells from MniPSCs. We also describe a method for expansion of enriched CD34 high cells with a putative long-term repopulating (LT)-HSC phenotype and show that these cells exhibit both myeloid and lymphoid differentiation potential ex vivo.
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MATERIALS AND METHODS

Macaque iPSC culture
Derivation of MniPSC lines 3 and 7 has been described. 12 Before differentiation, normal karyotype was validated and phenotype confirmed by flow cytometry and visual assessment of colony appearance. MniPSCs were passaged weekly at ratios of 1:2 to 1:4 based on colony density onto irradiated mouse embryonic fibroblast feeder layers (iMEFs) plated at a density of 6
x 10 5 cells per well of a 6-well plate. MniPSCs on iMEFs were fed daily with PSC media consisting of 1:1 DMEM:F12 supplemented with 20% knockout serum replacement, 1% MEM nonessential amino acids, 2 mM L-glutamine (all from Life Technologies), 0.1 mM 2-mercaptoethanol (Sigma), and 20 ng/mL human basic fibroblast growth factor (bFGF, R&D Systems), and passaged weekly with 200 U/mL Collagenase Type IV (Life Technologies) in DMEM:F12 containing 100 U/mL Dnase I (Sigma). All undifferentiated iPSC cultures were maintained at 37˚C in a humidified incubator (5% CO 2 , 20% O 2 ).
Hematopoietic mesoderm induction and differentiation
Before passage of MniPSCs to feeder-free conditions, MniPSCs on iMEFs were treated with 10 µM Y-27632 rock inhibitor (Calbiochem) for 1 hour, dissociated with 200 U/mL Collagenase Type IV plus Dnase I. Cells were passaged at ratios of 1:2 to 1:3 onto 6-well plates or 10-cm dishes (Costar) coated with 1:2 GFR matrigel (BD Bioscience), and cultured overnight in PSC media plus 20 ng/mL bFGF and 10 µM Y-27632 ( Figure 1A ). On day -1 relative to differentiation, cells were fed with PSC media plus 20 ng/mL bFGF. On day 0, 75-90% confluent MniPSC colonies were dissociated with 200 U/mL Collagenase Type IV plus 200 U/mL Dnase I, washed with DMEM:F12 media and scraped into clusters. Basal media formulation and BMP4 mediated mesoderm induction has been previously described for hESC differentiation.
20,21
MniPSC aggregates were suspended in complete (c)StemPRO media (StemPRO-34 plus supplement (Life Technologies), 2 mM L-glutamine, 50 µg/mL ascorbic acid (Sigma), 4 × 10 -4 M For personal use only. on July 15, 2017. by guest www.bloodjournal.org From 1-thioglycerol (Sigma) and 150 µg/mL transferrin (Roche)), supplemented with 10, 20, or 50 ng/mL BMP4 ( Figure 1A ) and cultured in low-cluster plates (Costar). CStemPRO was supplemented with human cytokines, indicated below and in panel A for each figure. All cytokines were recombinant human cytokines purchased from R&D Systems unless indicated.
On day 1, EBs were settled by gravity and suspended in cStemPRO with BMP4 (20 ng/mL) and bFGF (10 ng/mL). On day 4, EBs were settled by gravity and suspended in cStemPRO with 10 ng/mL each of VEGF and bFGF.
For hematopoietic specification, from day 8 onward cStemPRO media was supplemented with stem cell factor (SCF, 100 ng/mL, Miltenyi Biotech), interleukin (IL)-3 (20 ng/mL, Peprotech), IL-6 (20 ng/mL, Peprotech), IL-11 (50 ng/mL), erythropoietin (EPO, 4 U/mL, Peprotech), thrombopoietin (TPO, 20 ng/mL, Peprotech), and insulin like growth factor-1 (IGF-1, 25 ng/mL). Cultures were maintained in hypoxia (5% CO 2 / 5% O 2 / 90% N 2 ). In some experiments, 0.75 µM SR1 (Cellagen Technology, days 1-21 or 8-21) or 2 µM PGE2 (Cayman Chemical, days 1-21 or 1-8) were added at indicated time points (Figures 2A, 3A , 4A, and 5A).
The PGE2 concentration used (2 µM) has been tested in the context of hESC hematopoietic differentiation. 19 The SR1 concentration (0.75 µM) was selected based on our recent optimization studies expanding macaque cord blood, as well as bone marrow and peripheral blood derived CD34 + CD38 -HSCs ex vivo (manuscript in preparation). containing 50 µg/mL ascorbic acid, 100 µM 1-monothioglycerol, 20% FBS, 10 ng/mL SCF, 5 ng/mL each of FL and IL-7, maintained, passaged, and analyzed as previously described ( Figure 5A ). cell inoculation, cells were collected and analyzed by flow cytometry as described. 30 Background GFP levels detected in cells exposed to OP9DL1-GFP cell supernatant were subtracted from GFP percentages observed in MniPSC lymphoid cultures. For HIV p24 and SIV p27 tests, cell-free supernatants were diluted 1:6 or 1:100, respectively, in media and assayed with the p24 Antigen ELISA kit (Perkin Elmer) or the p27 Antigen ELISA kit (ZeptoMetrix 
Purification of CD34 high MniPSC-derived hematopoietic progenitor cells
RNA isolation and quantitative real-time RT-PCR
Total RNA was prepared with the RNeasy Plus Kit and treated with RNase-free DNase (all from Qiagen). RNA was reverse transcribed into cDNA using the Superscript III First-strand Synthesis System kit (Life Technologies) according to the manufacturer's protocol. Macaque-specific (human cross-reactive) primers (Table 1) were designed based on the annotated rhesus macaque genome (synthesized by IDT). For target sequences that lacked annotated confirmed or predicted sequences, oligonucleotides specific for the human sequences were used, with human SCL-and Brachyuryspecific primers already described.
3 QPCR was performed with 2X Power SYBR green master mix (Applied Biosystems) on a real time PCR system machine (Applied Biosystems 7500).
Statistical methods
Means and standard deviations were calculated, and Student's t-tests and ANOVA statistical tests performed where indicated using Microsoft Excel software version 12.3.2.
RESULTS
Titration of Bone Morphogenetic Protein 4 for efficient hematopoietic mesoderm induction of MniPSCs
Toward scaling up CD34 + cell production, we titrated BMP4 added during day 0 aggregation, which impacts efficiency of mesoderm induction 31 ( Figure 1A ). As the optimal BMP4 concentration may vary depending on the human ESC/iPSC line, we tested three BMP4
concentrations ( Figure 1C ). Although the total percentage of CD34 + cells was higher on day 21, the best viable cell yield was achieved on day 14. Only ~5% (<100,000) CD34 + cells co-expressed hematopoietic markers (CD31, CD45). Importantly, CD31, which is expressed on early hematoendothelial precursors, emerged before CD45, which is induced later and is associated with lineage commitment.
We next assessed myeloid and short-term hematopoietic potential in colony forming unit (CFU) assays. To determine the optimal Methocult formulation for MniPSC-HPCs, we tested three different formulations: H4230, historically used with human and pigtail macaque CD34 + cells, H4435, used with human ESC-derived hematopoietic progenitors, and a non-commercial formulation used with hESCs that has been previously described. 20, 21 MniPSCs induced with 20 ng/mL BMP4 gave rise to significantly more CFUs, displaying a 90% CFU-M and 10% CFU-GM phenotype. Similar CFU numbers and morphologies were noted for the three semi-solid media tested, therefore CFU data for the H4435 formulation only is shown ( Figure 1D ). CFUs peaked on day 14 and were significantly increased for cells induced in 20 ng/mL BMP4, coinciding with the highest CD34 + viable cell yield. BMP4 titration was also tested for hematopoietic induction of MniPSC line 7 and similar results were obtained (data not shown).
Treatment with PGE2 and SR1 enhance hematopoietic progenitor emergence and expansion
We next tested whether PGE2 32 or SR1, 14 which activate downstream pathways implicated in HSC emergence and homeostasis, respectively, would improve HPC formation from macaque iPSCs. We first evaluated the effect of PGE2 or SR1 on hematopoietic differentiation of MniPSC lines 3 and 7 ( Figure 2A ). We selected a previously published PGE2 concentration used in the context of hESC hematopoietic specification 19 and a SR1 concentration determined to be optimal for expansion of NHP CD34 + cells obtained from cord blood, peripheral blood and bone marrow (data not shown). PGE2 treatment nearly tripled the viable CD34 + cell yield in day 14
HPCs generated from MniPSC line 3 cultures ( Figures 2B and 2C ). Primitive hematopoietic cell (CD34 + CD45 + ) yields increased 4-and 2-fold, respectively, in PGE2 and SR1 treated MniPSC cultures with no negative impact on total CD34 + cell yield. Importantly, PGE2 treatment restricted to the first 8 days increased CD34 + cell yield without compromising CFUs ( Figure 2D ). Figure 3B and 3C). Hematopoietic colony forming potential doubled for sorted compared to unsorted HPCs ( Figure 3D ). CFUs generated from sorted CD34 + cells were 2-fold higher for line 7 compared to line 3, consistent with their CD45 + CD34 + CD31 low phenotype, which is associated with erythro-myeloid potential 33 ( Figure 3E ). In contrast, line 3 derived cells had a approached CFU counts obtained from unsorted macaque mobilized bone marrow ( Figure 3D ).
Close to 90% of the hematopoietic colonies had CFU-M morphology, with only 10% of colonies displaying CFU-GM morphology. MniPSC CD34 + cells formed hematopoietic zones 25 in OP9 stromal cell co-culture, which resemble cobblestone area forming cells ( Figure 3F ).
An optimized four-step protocol supports the expansion of MniPSC-derived HPCs with a putative LT-HSC phenotype
Based on stage-specific biologic roles of the prostaglandin pathway in early hematopoiesis and AhR signaling in HSC homeostasis, we wanted to determine whether sequential modulation of these pathways with PGE2 and SR1 would enhance emergence and expansion of putative HSCs. To clarify the effect of SR1 on HPC homeostasis, we tested whether a novel multi-step approach to HSC generation, purification and expansion would increase HPC yield. We hypothesized that early treatment with PGE2 would boost viable CD34 + cell yield, purification of CD34 high cells would enhance hematopoietic commitment by eliminating residual undifferentiated iPSCs, and subsequent SR1 treatment would expand the CD34 + putative HSCs ( Figure 4A ). We also developed a progenitor expansion media, which excludes endothelial (VEGF), erythroid (TPO, EPO) and myeloid (IL-3, IL-6) specific cytokines. To expand HPCs, we supplemented basal media with SCF, FL, IL-11, bFGF, and SR1 ( Figure 4A ).
As the results shown in Figure 3 indicate, MniPSC line 7 derived CD34 high cells have greater hematopoietic mesoderm potential compared to line 3, thus subsequent studies were conducted with MniPSC line 7. Toward scaling up HPC production, we also switched from a 6-well plate format to 10-cm dishes. To clarify the phenotype of MniPSC-derived primitive HPCs, we included hematopoietic cell-specific gene expression by qRT-PCR ( Figure 4B and Table 1) and a multi-parametric LT-HSC like phenotype which has been shown to identify human cord blood derived SCID repopulating cells (SRCs, CD34 + CD38 -Thy1 + CD45RA -CD49f + ). 34 Gene expression assays for mesoderm and hematopoietic transcription factors showed that Brachyury, CDX4, and GATA2 mRNA peaked on day 1 while CDX1, CDX2, and HOXA9 peaked on day 4, followed by SCL on day 8. Cell surface markers Flt3 and CD34 peaked on day 4 and 6, respectively. On days 4, 6, and 8 of differentiation, all CD34 + cells were also CD38 -and a fraction of the CD34 + cells co-expressed CD49f as determined by flow cytometry ( Figure   4C ). CD34 + cell yield was highest on day 4 (4.5 million CD34 + cells per 10-cm plate) and Figure   5C and Table 1 ). Importantly, RAG-1 mRNA was upregulated 10 7 -fold in MniPSC lymphoid-like cells, suggesting an early lymphoid progenitor state had been achieved ( Figure 5C Figure 5F ). The SIV p27 antigen capture ELISA, which measures viral replication, indicated high p27 levels in the media of both Mn CD4 + (2.2 x 10 4 pg/mL) and MniPSC lymphoid-like cells (2.4 x 10 3 pg/mL) (~9-fold difference) ( Figure S1D ). These results indicate that NHP iPSCs give rise to lymphoid-like cells that respond to co-stimulation and support SHIV entry and replication ex vivo.
DISCUSSION
We have developed a novel hematopoietic differentiation, enrichment, and expansion protocol to facilitate the emergence and expansion of HPCs from MniPSCs. We report that sequential treatment with PGE2 followed by SR1 increases production of CD34 high cells, which display a cell surface marker phenotype similar to putative LT-HSCs. Purified CD34 high cells While scale up for such a transplant will be a challenge, other issues must be addressed to translate iPSC technology to a larger physiologic system. These include selection of the specific iPSC line, the passage number to be used in transplantation, and quality control of the reagents used for differentiation. In our studies, both the passage number and clonal line of iPSCs impacted efficiency of differentiation and cell yield. For each line, it is likely that the expansion protocol will have to be further optimized to reach minimum cell doses for transplantation. Additionally, for the small-scale studies presented herein, we have used previously validated batches of reagents. Scale-up for the monkey transplant will require liters of StemPRO media and several grams of cytokines for differentiation.
If human/mouse xenograft data are predictive of engraftment potential of HSCs derived from various sources (i.e. UCB, BM, iPSCs), then chemical modification, co-culture methods, genetic manipulation, and/or higher cell doses will likely be required to approach the therapeutic benefit that is currently achievable with UCB and BM-derived HSC transplantation. To this end, in vivo selection or expansion will likely be required for long-term engraftment and contribution to hematopoiesis, which raises additional concerns. While it is straightforward to gene modify iPSCs, we have observed loss of transgene expression after serial passaging and lineage commitment, which could impede iPSC-related gene therapy applications. Finally, given the somewhat undefined repopulation potential of PSC-derived putative HSCs, transplantation of a more phenotypically distinct hematopoietic lineage, such as a purified lymphocyte population, may be more easily translatable to a large animal model and eventual patient population, including HIV/AIDS patients. Conflict-of-interest disclosure: The authors declare no competing financial interests.
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